What is Promethazine?
Promethazine is a first-generation antihistamine (phenothiazine derivative) with H1-receptor antagonist properties that also exhibits sedative, antiemetic, anti-motion sickness, and anticholinergic effects—but it should generally be avoided in favor of safer alternatives due to significant risks of sedation, performance impairment, and serious adverse effects. 1, 2
Drug Classification and Mechanism
Promethazine is a histamine H1 receptor competitive antagonist first approved in 1951. Beyond antihistaminic activity, it possesses:
- Sedative/hypnotic properties
- Antiemetic effects
- Anti-motion sickness activity
- Antimuscarinic (anticholinergic) effects 3
FDA-Approved Indications
According to FDA labeling, promethazine is indicated for 2:
- Allergic conditions (rhinitis, urticaria)
- Motion sickness (prophylaxis and treatment)
- Nausea and vomiting (various etiologies)
- Sedation (preoperative, postoperative, obstetrical)
- Adjunct to analgesia (pre- and postoperative settings)
Dosing
Adults 2:
- Allergy: 25 mg at bedtime, or 12.5 mg before meals and at bedtime; may use 6.25-12.5 mg three times daily
- Motion sickness: 25 mg twice daily (first dose 30-60 minutes before travel, repeat 8-12 hours later)
- Nausea/vomiting: 25 mg; may repeat every 4-6 hours as needed
- Sedation: 25-50 mg at bedtime or preoperatively
Pediatric 2:
- Motion sickness: 12.5-25 mg twice daily
- Nausea/vomiting: 0.5 mg per pound of body weight, adjusted for age and severity
- Sedation: 12.5-25 mg at bedtime
Critical Contraindications
Absolute Contraindications 2:
- Children under 2 years of age (BLACK BOX WARNING—risk of fatal respiratory depression)
- Comatose states
- Known hypersensitivity to promethazine or phenothiazines
- Treatment of lower respiratory tract symptoms including asthma
Relative Contraindications/High-Risk Populations 1:
- Older adults: Increased risk of falls, fractures, subdural hematomas, cognitive impairment
- Narrow-angle glaucoma (anticholinergic effects)
- Benign prostatic hypertrophy
- Patients requiring alertness (drivers, workers operating machinery)
Serious Safety Concerns
Injectable Form Risks 3, 4:
The FDA issued updated labeling in December 2023 emphasizing that intramuscular administration is preferred over intravenous due to risk of:
- Tissue necrosis
- Gangrene requiring amputation
- Severe injury from extravasation or inadvertent intra-arterial injection
Patient safety organizations (ISMP, ASHP) have called for removal of injectable promethazine from hospital formularies 4.
CNS and Performance Impairment 1:
- Sedation and drowsiness occur in many patients, even without subjective awareness
- Impaired driving: Drivers taking first-generation antihistamines are 1.5 times more likely to be responsible for fatal automobile accidents
- Occupational accidents and decreased work productivity
- Impaired learning in children
- Effects persist into the next day even with bedtime dosing due to prolonged half-life
- Paradoxical CNS stimulation may occur, particularly in children
Anticholinergic Effects 1:
- Dry mouth and eyes
- Constipation
- Urinary retention
- Increased risk of narrow-angle glaucoma
- Anticholinergic delirium in overdose 5
Mortality Risk in COPD 6:
A 2023 nationwide registry study found promethazine-treated COPD patients had:
- 42% increased risk of severe exacerbations and death (HR 1.42, p<0.0001)
- 53% increased risk of death alone (HR 1.53, p<0.0001)
- Dose-dependent risk: Patients using ≥400 tablets/year had HR 2.15 for adverse outcomes
Addiction Potential 5, 7:
Despite being labeled "non-addictive," promethazine has demonstrated:
- Recreational use potential
- Increasing overdose cases (Sweden saw 7-fold increase in overdoses over a decade)
- Problematic use patterns in psychiatric populations
Why Second-Generation Antihistamines Are Preferred
For allergic rhinitis and other antihistamine-responsive conditions, second-generation antihistamines (fexofenadine, cetirizine, loratadine, olopatadine) are strongly preferred over promethazine. 1
The 2008 Joint Task Force Practice Parameter explicitly states that second-generation antihistamines should be used preferentially because they:
- Cause minimal to no sedation 8
- Do not impair psychomotor function 8
- Lack anticholinergic effects
- Have equivalent or superior antihistaminic efficacy 8
The guideline specifically recommends against the AM/PM strategy of combining second-generation antihistamines in the morning with first-generation agents at night, as this does not prevent daytime impairment. 1
Better Alternatives
For Nausea/Vomiting 9, 4:
- Ondansetron (4-8 mg IV/PO): No sedation, no black box warning, available in orally disintegrating tablets, superior safety profile
- Low-dose promethazine (6.25 mg IV) if ondansetron unavailable, though this still carries risks 10
For Sleep 7:
- Cognitive-behavioral therapy for insomnia (CBT-I): NICE first-line recommendation
- Melatonin: Safer alternative with better long-term outcomes
- Promethazine impedes psychological/behavioral sleep interventions and has unacceptable side effects for psychiatric patients
For Allergies 1:
- Fexofenadine, cetirizine, loratadine, olopatadine: All second-generation options with superior safety profiles
Common Pitfalls to Avoid
- Never use in children under 2 years (fatal respiratory depression risk)
- Don't assume bedtime dosing prevents next-day impairment—it doesn't 1
- Avoid in older adults whenever possible due to fall risk and cognitive effects
- Don't use injectable form IV unless absolutely necessary—prefer IM route and ensure proper dilution 3, 4
- Don't prescribe for COPD patients—associated with increased mortality 6
- Warn patients about driving and operating machinery—impairment occurs even without perceived drowsiness
- Don't use for insomnia in psychiatric patients—addiction potential and interference with evidence-based sleep interventions 7
Before prescribing promethazine, physicians must ensure patients understand both the potential for adverse effects and the availability of safer alternatives with lower likelihood of harm. 1